Sanofi’s New CEO Faces Pressure to Revitalize Drug Pipeline

Sanofi’s newly appointed chief executive faces mounting expectations to strengthen the pharmaceutical company’s drug development pipeline. Investors are closely tracking late-stage trial progress and regulatory milestones. Analysts noted that competitive pressures and pricing scrutiny in key markets add complexity to strategic decisions. The leadership transition comes at a critical time as the company seeks sustainable revenue growth beyond existing blockbuster therapies.